| Name | Title | Contact Details |
|---|
CAC Group operates in two distinct sectors. The first entity, CAC Group (Insurance & Advisory Services), is a prominent insurance broker and advisor. They specialize in customized solutions for insurance and capital markets, offering advisory and placement services for complex risk management. They also provide bespoke financial solutions through CAC Capital, focusing on private finance and structured offerings. In August 2024, they launched a new brand identity to reflect their expanded capabilities. The second entity, CAC Holdings Corporation, is a Japanese IT services conglomerate established in 1966. With 23 subsidiaries worldwide, it provides IT system construction, operation, and strategic consulting for enterprises. The company is led by President and CEO Ryota Nishimori and has a consolidated workforce of 4,653 employees. As of December 2024, CAC Holdings reported a capital of ¥3.7 billion and consolidated sales of ¥52.06 billion.
Oden Machinery, Inc. provides customers worldwide with liquid filling and processing machinery backed by over three decades of industry-leading innovation in design and engineering solutions. Oden is a leading U.S. manufacturer of filling and processing machinery for the liquid products markets and provides complete turnkey liquid packaging lines. Custom designed systems for form/fill/seal, bag-in-box, retort, explosion proof, and other specialized liquid packaging applications are also available. In August 2010, Oden partnered with Green Frontier LLC to help companies optimize their liquid processing operations and reduce their impact on the environment. The Oden Process Equipment Group offers continuous stream digital blending systems, automated batch addition systems, and liquid product transfer systems, all designed to reduce labor costs, enhance product quality, increase production capacity, and decrease generation of waste and scrap. Our customers businesses span a broad range of industries, including pharmaceutical, personal care products, food processing, household products, general industrial, automotive products, petroleum products, and the chemical processing industries. If your packaging/processing operations include filling or processing liquid products, we encourage you to visit www.odencorp.com. If you need an off the shelf" machine or require highly specialized machinery give us a call, 800-658-3622.
DGA Group is a global advisory firm that helps clients protect – and grow – what they have built in todays complex business environment. We understand the challenges and opportunities in an increasingly regulated and interconnected world. Leveraging the expertise and experience of our team at Albright Stonebridge Group, a leader in global strategy and commercial diplomacy, and a deep bench of communications, public affairs, government relations and business intelligence consultants, we help clients navigate and shape global policy, reputational and financial issues.
We are the premier, professional rugby team in the South. The NOLA Gold is the New Orleans franchise of Major League Rugby.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.